{"changeSha256":"7de8842d53bb4ba78de7aba28bc8198a404dbe1172abede4081d7ace979e1cb5","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Victoza, Saxenda and generic versions","before":"U.S. label record","field":"Status"},{"after":"A GLP-1 receptor agonist approved by FDA as Victoza and Saxenda, with approved generic versions. Large randomized trials support its weight-management and cardiovascular evidence.","before":"A GLP-1 receptor agonist. This profile cites a U.S. label record.","field":"Profile summary"},{"after":"The cited generic weight-management label covers adults and children aged 12 and older with obesity, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA proposed in April 2026 to exclude liraglutide from the 503B bulks list.","before":"The cited DailyMed label identifies Liraglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"Saxenda, Victoza","before":"Saxenda","field":"Related names"},{"after":"dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-glp1-label-warning-request-2026, fda-drugs-nda022341-2010-01-25-97e5fbcce57e, fda-drugs-nda206321-2014-12-23-a195c56028d5, fda-drugs-anda215503-2024-12-23-56b69e4fa52c, fda-glp1-bulks-proposal-2026, journal-pmid-27295427","before":"dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-glp1-label-warning-request-2026","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6]; U.S. Food and Drug Administration [sources: fda-drugs-nda022341-2010-01-25-97e5fbcce57e, fda-glp1-bulks-proposal-2026]","before":"U.S. National Library of Medicine [sources: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6]","field":"Named organizations"},{"after":"name: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; aliases: fda-glp1-label-warning-request-2026, fda-drugs-nda022341-2010-01-25-97e5fbcce57e; category: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; status: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-drugs-nda022341-2010-01-25-97e5fbcce57e, fda-drugs-nda206321-2014-12-23-a195c56028d5, fda-drugs-anda215503-2024-12-23-56b69e4fa52c; summary: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-drugs-nda022341-2010-01-25-97e5fbcce57e, fda-drugs-nda206321-2014-12-23-a195c56028d5, fda-drugs-anda215503-2024-12-23-56b69e4fa52c, journal-pmid-27295427; evidenceNote: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-glp1-bulks-proposal-2026","before":"name: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; aliases: fda-glp1-label-warning-request-2026; category: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; status: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; summary: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; evidenceNote: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/liraglutide/versions/4/","version":4},"id":"profile:liraglutide:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the liraglutide label and the Drugs@FDA approval records, and added the LEADER trial report and FDA’s April 2026 503B proposal.","peptideSlugs":["liraglutide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/liraglutide/v3.json","sha256":"d2d3e47baf2152b4826112d1c4873172e6d6a0534533743e8c4dfd402f7b3b88"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/liraglutide/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"Liraglutide injection, solution · SPL version 6 · published 2026-07-14","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=22c86976-9657-4dd0-8fff-0c3f3f08357c&version=6","verifiedAt":"2026-07-22"},{"id":"fda-drugs-nda022341-2010-01-25-97e5fbcce57e","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA022341 · original submission status AP · 2010-01-25 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA022341%22&limit=1","verifiedAt":"2026-08-14"},{"id":"journal-pmid-27295427","name":"The New England Journal of Medicine","sourceClass":"A","title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER, 2016) · PMID 27295427","url":"https://doi.org/10.1056/NEJMoa1603827","verifiedAt":"2026-11-14"}],"subject":{"slug":"liraglutide","type":"profile"}}
